Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 4 clients • 5 examiners • 5 art units • 0 of 5 (0%) have an AI response strategy ready
Singleton Law, PLLC has 162 career applications, with a focus on the Biotechnology & Pharmaceuticals technology area. The firm maintains a resolved allowance rate of 92.45 percent. This 92.45 percent allowance rate is an achievement across the firm's 162 career applications.
The firm currently has 5 pending office actions under review. On average, it takes 4.35 office actions per allowance to reach a grant. This 4.35 figure reflects the negotiation required in biotechnology prosecution. The 5 pending office actions represent the firm's current active queue in the life sciences sector.
The 4.35 office actions per allowance metric highlights the firm's approach to overcoming rejections. Combined with a 92.45 percent allowance rate, the data shows that the firm is effective at securing patents in Biotechnology & Pharmaceuticals. With 162 career applications, the firm has established a specialized practice for its clients.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 5 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 1 | 55.0% | +28.0% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
| BOWERS, ERIN M | 1 | 54.7% | +9.8% |
| QIAN, CELINE X | 1 | 47.5% | +17.2% |
| WOZNICKI, JACQUELINE | 1 | 49.8% | +26.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17765661 | Direct Cardiac Compression Device with Improved Durability | WOZNICKI, JACQUELINE | 14d |
| 18883789 | METHOD TO INCREASE DRUG SUBSTANCE YIELD | BOWERS, ERIN M | 46d |
| 19361525 | Unique Interferon Alpha 2B And New Method Of Making Thereof | MARVICH, MARIA | — |
| 18960416 | CANNABIS EXTRACT COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY FOR SKIN CARE | SCOTLAND, REBECCA LYNN | — |
| 18555503 | INHIBITORY RNA FOR THE CONTROL OF PHYTOPATHOGENS | QIAN, CELINE X | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17765661 | Direct Cardiac Compression Device with Improved Durability | WOZNICKI, JACQUELINE | 14d |
| 19361525 | Unique Interferon Alpha 2B And New Method Of Making Thereof | MARVICH, MARIA | — |
| 18555503 | INHIBITORY RNA FOR THE CONTROL OF PHYTOPATHOGENS | QIAN, CELINE X | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Pharmaessentia Corporation | 2 |
| Regenerex Pharma, Inc. | 1 |
| University of California | 1 |
| CORINNOVA INCORPORATED | 1 |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1615 | 1 |
| 1653 | 1 |
| 1663 | 1 |
| 3774 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19361525 | Unique Interferon Alpha 2B And New Method Of Making Thereof | Pharmaessentia Corporation | MARVICH, MARIA | 1634 | §102§112 | Non-Final OA | — | Pending | Oct 17, 2025 |
| 18960416 | CANNABIS EXTRACT COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY FOR SKIN CARE | Regenerex Pharma, Inc. | SCOTLAND, REBECCA LYNN | 1615 | §102§103§112Other | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18883789 | METHOD TO INCREASE DRUG SUBSTANCE YIELD | Pharmaessentia Corporation | BOWERS, ERIN M | 1653 | §103§112 | Final Rejection | 46d | Pending | Sep 12, 2024 |
| 18555503 | INHIBITORY RNA FOR THE CONTROL OF PHYTOPATHOGENS | The Regents of the University of California | QIAN, CELINE X | 1663 | §102§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 17765661 | Direct Cardiac Compression Device with Improved Durability | Corinnova Incorporated | WOZNICKI, JACQUELINE | 3774 | §103§112 | Final Rejection | 14d | Pending | Mar 31, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial92.5% of resolved applications prosecuted by Singleton Law, Pllc were allowed, across 162 applications in USPTO records.
4.35 office actions per allowed application on average.
5 pending office actions as of October 2026, for 4 clients, before 5 examiners in 5 art units.
